Tasha Barr

Tasha Barr

Auto-generated profile, based on publicly available information

Tasha Barr

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SMShoubao Ma
Shoubao Ma
BSBaofa Sun
Baofa Sun
SDSongqi Duan
Songqi Duan
JHJingjing Han
Jingjing Han
TBTasha Barr
Tasha Barr
JYJianhua Yu
Jianhua Yu

18 May 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
RMRui Ma
Rui Ma
TLTing Lu
Ting Lu
ZLZhenlong Li
Zhenlong Li
KTKun-Yu Teng
Kun-Yu Teng
AMAnthony G. Mansour
Anthony G. Mansour
JYJianhua Yu
Jianhua Yu
IL15 is a pleiotropic cytokine with multiple roles that improve immune responses to tumor cells. Oncolytic viruses (OV) specifically lyse tumors and activate immune responses. Systemic administration of IL15 or its complex with the IL15Rα and chimeric antigen receptor (CAR) natural killer (NK) cells are currently being tested in the clinic. Here, we generated a herpes simplex 1–based OV-expressing human IL15/IL15Rα sushi domain fusion protein (named OV-IL15C), as well as off-the-shelf EGFR-CAR NK cells, and studied their monotherapy and combination efficacy in vitro and in multiple glioblastoma (GBM) mouse models. In vitro, soluble IL15/IL15Rα complex was secreted from OV-IL15C–infected GBM cells, which promoted GBM cytotoxicity and improved survival of NK and CD8+ T cells. Frozen, readily available off-the-shelf EGFR-CAR NK cells showed enhanced killing of tumor cells compared with empty vector–transduced NK cells. In vivo, OV-IL15C significantly inhibited tumor growth and prolonged survival of GBM-bearing mice in the presence of CD8+ T cells compared with parental OV. OV-IL15C plus EGFR-CAR NK cells synergistically suppressed tumor growth and significantly improved survival compared with either monotherapy, correlating with increased intracranial infiltration and activation of NK and CD8+ T cells and elevated persistence of CAR NK cells in an immunocompetent model. Collectively, OV-IL15C and off-the-shelf EGFR-CAR NK cells represent promising therapeutic strategies for GBM treatment to improve the clinical management of this devastating disease. Significance: The combination of an oncolytic virus expressing the IL15/IL15Rα complex and frozen, ready-to-use EGFR-CAR NK cells elicits strong antitumor responses in glioblastoma.

23 June 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SMShoubao Ma
Shoubao Ma
JYJiazhuo Yan
Jiazhuo Yan
TBTasha Barr
Tasha Barr
JZJianying Zhang
Jianying Zhang
ZCZhenhua Chen
Zhenhua Chen
JYJianhua Yu
Jianhua Yu
N 6-methyladenosine (m6A) is the most prevalent posttranscriptional modification on RNA. NK cells are the predominant innate lymphoid cells that mediate antiviral and antitumor immunity. However, whether and how m6A modifications affect NK cell immunity remain unknown. Here, we discover that YTHDF2, a well-known m6A reader, is upregulated in NK cells upon activation by cytokines, tumors, and cytomegalovirus infection. Ythdf2 deficiency in NK cells impairs NK cell antitumor and antiviral activity in vivo. YTHDF2 maintains NK cell homeostasis and terminal maturation, correlating with modulating NK cell trafficking and regulating Eomes, respectively. YTHDF2 promotes NK cell effector function and is required for IL-15–mediated NK cell survival and proliferation by forming a STAT5–YTHDF2 positive feedback loop. Transcriptome-wide screening identifies Tardbp to be involved in cell proliferation or survival as a YTHDF2-binding target in NK cells. Collectively, we elucidate the biological roles of m6A modifications in NK cells and highlight a new direction to harness NK cell antitumor immunity.

31 March 2023 in Science Immunology
Verified
Journal Article
Closed access
SMShoubao Ma
Shoubao Ma
JHJingjing Han
Jingjing Han
ZLZhenlong Li
Zhenlong Li
SXSai Xiao
Sai Xiao
JZJianying Zhang
Jianying Zhang
JYJianhua Yu
Jianhua Yu
Spliced X-box–binding protein 1 (XBP1s) is an essential transcription factor downstream of interleukin-15 (IL-15) and AKT signaling, which controls cell survival and effector functions of human natural killer (NK) cells. However, the precise mechanisms, especially the downstream targets of XBP1s, remain unknown. In this study, by using XBP1 conditional knockout mice, we found that XBP1s is critical for IL-15–mediated NK cell survival but not proliferation in vitro and in vivo. Mechanistically, XBP1s regulates homeostatic NK cell survival by targeting PIM-2, a critical anti-apoptotic gene, which in turn stabilizes XBP1s protein by phosphorylating it at Thr 58 . In addition, XBP1s enhances the effector functions and antitumor immunity of NK cells by recruiting T-bet to the promoter region of Ifng . Collectively, our findings identify a previously unknown mechanism by which IL-15–XBP1s signaling regulates the survival and effector functions of NK cells.

29 July 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
TLTing Lu
Ting Lu
RMRui Ma
Rui Ma
ZLZhenlong Li
Zhenlong Li
AMAnthony G. Mansour
Anthony G. Mansour
KTKun-Yu Teng
Kun-Yu Teng
JYJianhua Yu
Jianhua Yu
Trogocytosis is a fast, cell–cell contact-dependent uptake of membrane patches and associated molecules by one cell from another. Here, we report our investigation of trogocytosis of TYRO3, a cell membrane protein, from tumor target cells to natural killer (NK) cells and the associated functional consequences for NK cells. We found that although NK cells did not express endogenous TYRO3 on the cell surface, activated NK cells rapidly acquired TYRO3 from tumor cells via trogocytosis in vitro and in vivo. NK cells that acquired TYRO3, which we termed TYRO3+ NK cells, had significantly enhanced cytotoxicity and IFNγ production as well as higher expression of some activated surface markers compared with TYRO3− NK cells. Furthermore, the activation status of NK cells and TYRO3 expression levels on donor cells, either endogenous or ectopic, positively correlated with trogocytosis levels. When the antigen-presenting cell (APC) K562 leukemia cell line, a feeder cell line to expand NK cells, overexpressed TYRO3, TYRO3 was transferred to NK cells via trogocytosis, which improved NK-cell proliferation ex vivo. This provides a strategy to manufacture NK cells or their engineered counterparts, such as chimeric antigen receptor NK cells, for the treatment of cancer or infectious diseases.

8 January 2021 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
TLTing Lu
Ting Lu
LCLi Chen
Li Chen
AMAnthony G Mansour
Anthony G Mansour
MYMelissa J. Yu
Melissa J. Yu
NBNoah Brooks
Noah Brooks
MCMichael Caligiuri
Michael Caligiuri
The E3 ubiquitin ligase Cbl-b has been characterized as an intracellular checkpoint in T cells; however, the function of Cbl-b in primary human NK cells, an innate immune anti-tumor effector cell, is not well defined. In this study, we show that the expression of Cbl-b is significantly upregulated in primary human NK cells activated by IL-15, IL-2, and the human NK cell–sensitive tumor cell line K562 that lacks MHC class I expression. Pretreatment with JAK or AKT inhibitors prior to IL-15 stimulation reversed Cbl-b upregulation. Downregulation of Cbl-b resulted in significant increases in granzyme B and perforin expression, IFN-γ production, and cytotoxic activity against tumor cells. Collectively, we demonstrate upregulation of Cbl-b and its inhibitory effects in IL-15/IL-2/K562–activated human NK cells, suggesting that Cbl-b plays a negative feedback role in human NK cells.